FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804198857> ?p ?o ?g. }

• W2804198857 endingPage "1265" @default.
• W2804198857 startingPage "1256" @default.
• W2804198857 abstract "CVD remains the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). CKD profoundly affects HDL composition and functionality, but whether abnormal HDL independently contributes to cardiovascular events in CKD patients remains elusive. In the present study, we assessed whether compositional and functional properties of HDL predict cardiovascular outcome among 526 nondialysis CKD patients who participate in the CARE FOR HOMe study. We measured HDL cholesterol, the content of HDL-associated proinflammatory serum amyloid A (SAA), and activities of the HDL enzymes paraoxonase and lipoprotein-associated phospholipase A2 (Lp-PLA2). In addition, we assessed the antioxidative activity of apoB-depleted serum. During a mean follow-up of 5.1 ± 2.1 years, 153 patients reached the predefined primary endpoint, a composite of atherosclerotic cardiovascular events including cardiovascular mortality and death of any cause. In univariate Cox regression analyses, lower HDL-cholesterol levels, higher HDL-associated SAA content, and lower paraoxonase activity predicted cardiovascular outcome, while Lp-PLA2 activity and antioxidative capacity did not. HDL-cholesterol and HDL-paraoxonase activity lost their association with cardiovascular outcome after adjustment for traditional cardiovascular and renal risk factors, while SAA lost its association after further adjustment for C-reactive protein. In conclusion, our data suggest that neither HDL quantity nor HDL composition or function independently predict cardiovascular outcome among nondialysis CKD patients. CVD remains the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). CKD profoundly affects HDL composition and functionality, but whether abnormal HDL independently contributes to cardiovascular events in CKD patients remains elusive. In the present study, we assessed whether compositional and functional properties of HDL predict cardiovascular outcome among 526 nondialysis CKD patients who participate in the CARE FOR HOMe study. We measured HDL cholesterol, the content of HDL-associated proinflammatory serum amyloid A (SAA), and activities of the HDL enzymes paraoxonase and lipoprotein-associated phospholipase A2 (Lp-PLA2). In addition, we assessed the antioxidative activity of apoB-depleted serum. During a mean follow-up of 5.1 ± 2.1 years, 153 patients reached the predefined primary endpoint, a composite of atherosclerotic cardiovascular events including cardiovascular mortality and death of any cause. In univariate Cox regression analyses, lower HDL-cholesterol levels, higher HDL-associated SAA content, and lower paraoxonase activity predicted cardiovascular outcome, while Lp-PLA2 activity and antioxidative capacity did not. HDL-cholesterol and HDL-paraoxonase activity lost their association with cardiovascular outcome after adjustment for traditional cardiovascular and renal risk factors, while SAA lost its association after further adjustment for C-reactive protein. In conclusion, our data suggest that neither HDL quantity nor HDL composition or function independently predict cardiovascular outcome among nondialysis CKD patients. There is unequivocal evidence of an inverse association between plasma HDL cholesterol (HDL-C) concentrations and the risk of CVD, a finding that has led to the hypothesis that HDL protects from CVD. In line with the HDL hypothesis, HDL exhibits many potential antiatherogenic properties (1.Toth P.P. Barter P.J. Rosenson R.S. Boden W.E. Chapman M.J. Cuchel M. D'Agostino Sr., R.B. Davidson M.H. Davidson W.S. Heinecke J.W. et al.High-density lipoproteins: a consensus statement from the National Lipid Association.J. Clin. Lipidol. 2013; 7: 484-525Abstract Full Text Full Text PDF PubMed Scopus (245) Google Scholar). HDL can act as an acceptor of cellular cholesterol, which constitutes the first step in a pathway known as reverse cholesterol transport (2.Yancey P.G. Bortnick A.E. Kellner-Weibel G. de la Llera-Moya M. Phillips M.C. Rothblat G.H. Importance of different pathways of cellular cholesterol efflux.Arterioscler. Thromb. Vasc. Biol. 2003; 23: 712-719Crossref PubMed Scopus (438) Google Scholar). In addition, HDL isolated from healthy subjects shows potent antiinflammatory and antioxidant properties (3.Barter P.J. Nicholls S. Rye K.A. Anantharamaiah G.M. Navab M. Fogelman A.M. Antiinflammatory properties of HDL.Circ. Res. 2004; 95: 764-772Crossref PubMed Scopus (1056) Google Scholar). apoA-I is the most important structural protein of HDL with antioxidant properties (4.Kontush A. Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities.Curr. Opin. Lipidol. 2010; 21: 312-318Crossref PubMed Scopus (217) Google Scholar, 5.Panzenböck U. Stocker R. Formation of methionine sulfoxide-containing specific forms of oxidized high-density lipoproteins.Biochim. Biophys. Acta. 2005; 1703: 171-181Crossref PubMed Scopus (65) Google Scholar). Consequently, HDL has the capacity to inhibit the oxidative modification of LDL and thereby reduce the atherogenicity of these lipoproteins (4.Kontush A. Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities.Curr. Opin. Lipidol. 2010; 21: 312-318Crossref PubMed Scopus (217) Google Scholar). HDL-associated paraoxonase shows antiinflammatory (6.Mackness B. Mackness M. The antioxidant properties of high-density lipoproteins in atherosclerosis.Panminerva Med. 2012; 54: 83-90PubMed Google Scholar, 7.Efrat M. Aviram M. Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis—a protective role for HDL phospholipids.Adv. Exp. Med. Biol. 2010; 660: 153-166Crossref PubMed Scopus (46) Google Scholar) and endothelial protective activities (8.Besler C. Heinrich K. Rohrer L. Doerries C. Riwanto M. Shih D.M. Chroni A. Yonekawa K. Stein S. Schaefer N. et al.Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.J. Clin. Invest. 2011; 121: 2693-2708Crossref PubMed Scopus (445) Google Scholar). Chronic kidney disease (CKD) profoundly alters enzyme activities involved in HDL metabolism, affecting particle maturation and remodeling, thereby changing HDL composition and function (9.Birner-Gruenberger R. Schittmayer M. Holzer M. Marsche G. Understanding high-density lipoprotein function in disease: recent advances in proteomics unravel the complexity of its composition and biology.Prog. Lipid Res. 2014; 56: 36-46Crossref PubMed Scopus (80) Google Scholar, 10.Marsche G. Saemann M.D. Heinemann A. Holzer M. Inflammation alters HDL composition and function: implications for HDL-raising therapies.Pharmacol. Ther. 2013; 137: 341-351Crossref PubMed Scopus (87) Google Scholar, 11.Holzer M. Schilcher G. Curcic S. Trieb M. Ljubojevic S. Stojakovic T. Scharnagl H. Kopecky C.M. Rosenkranz A.R. Heinemann A. et al.Dialysis modalities and HDL composition and function.J. Am. Soc. Nephrol. 2015; 26: 2267-2276Crossref PubMed Scopus (62) Google Scholar). These compositional alterations include enrichment of uremic HDL with proinflammatory acute-phase protein serum amyloid A (SAA) and lipoprotein-associated phospholipase A2 (Lp-PLA2) content (12.Holzer M. Birner-Gruenberger R. Stojakovic T. El-Gamal D. Binder V. Wadsack C. Heinemann A. Marsche G. Uremia alters HDL composition and function.J. Am. Soc. Nephrol. 2011; 22: 1631-1641Crossref PubMed Scopus (221) Google Scholar, 13.Weichhart T. Kopecky C. Kubicek M. Haidinger M. Doller D. Katholnig K. Suarna C. Eller P. Tolle M. Gerner C. et al.Serum amyloid A in uremic HDL promotes inflammation.J. Am. Soc. Nephrol. 2012; 23: 934-947Crossref PubMed Scopus (181) Google Scholar), whereas antiinflammatory HDL-paraoxonase content and activity are markedly reduced (11.Holzer M. Schilcher G. Curcic S. Trieb M. Ljubojevic S. Stojakovic T. Scharnagl H. Kopecky C.M. Rosenkranz A.R. Heinemann A. et al.Dialysis modalities and HDL composition and function.J. Am. Soc. Nephrol. 2015; 26: 2267-2276Crossref PubMed Scopus (62) Google Scholar). Of note, despite substantial experimental work on HDL in CKD, the clinical implications of most of these structural and functional alterations of HDL have remained enigmatic up to now. Earlier work on HDL functionality largely focused on its promotion of cholesterol efflux from macrophages (HDL-C efflux capacity). In the general population (14.Rohatgi A. Khera A. Berry J.D. Givens E.G. Ayers C.R. Wedin K.E. Neeland I.J. Yuhanna I.S. Rader D.R. de Lemos J.A. et al.HDL cholesterol efflux capacity and incident cardiovascular events.N. Engl. J. Med. 2014; 371: 2383-2393Crossref PubMed Scopus (970) Google Scholar, 15.Saleheen D. Scott R. Javad S. Zhao W. Rodrigues A. Picataggi A. Lukmanova D. Mucksavage M.L. Luben R. Billheimer J. et al.Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study.Lancet Diabetes Endocrinol. 2015; 3: 507-513Abstract Full Text Full Text PDF PubMed Scopus (348) Google Scholar) and among individuals at elevated cardiovascular risk (16.Ritsch A. Scharnagl H. Marz W. HDL cholesterol efflux capacity and cardiovascular events.N. Engl. J. Med. 2015; 372: 1870-1871PubMed Google Scholar), HDL cholesterol efflux capacity was inversely associated with incident cardiovascular events, even after adjusting for HDL-C levels. Importantly, these associations were not observed among CKD patients within the CARE FOR HOMe (Cardiovascular and Renal Outcome in CKD 2-4 Patients–The Fourth Homburg evaluation) (17.Bauer L. Kern S. Rogacev K.S. Emrich I.E. Zawada A. Fliser D. Heinemann A. Heine G.H. Marsche G. HDL cholesterol efflux capacity and cardiovascular events in patients with chronic kidney disease.J. Am. Coll. Cardiol. 2017; 69: 246-247Crossref PubMed Scopus (33) Google Scholar) and the German Diabetes Dialysis Study (4D Study) (18.Kopecky C. Ebtehaj S. Genser B. Drechsler C. Krane V. Antlanger M. Kovarik J.J. Kaltenecker C.C. Parvizi M. Wanner C. et al.HDL cholesterol efflux does not predict cardiovascular risk in hemodialysis patients.J. Am. Soc. Nephrol. 2017; 28: 769-775Crossref PubMed Scopus (42) Google Scholar). Given that oxidative stress and a chronic inflammatory state are major nontraditional risk factors among CKD patients (19.Locatelli F. Canaud B. Eckardt K.U. Stenvinkel P. Wanner C. Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome.Nephrol. Dial. Transplant. 2003; 18: 1272-1280Crossref PubMed Scopus (621) Google Scholar, 20.Cachofeiro V. Goicochea M. de Vinuesa S.G. Oubina P. Lahera V. Luno J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease.Kidney Int. Suppl. 2008; 111: S4-S9Abstract Full Text Full Text PDF PubMed Scopus (443) Google Scholar, 21.Marsche G. Frank S. Hrzenjak A. Holzer M. Dirnberger S. Wadsack C. Scharnagl H. Stojakovic T. Heinemann A. Oettl K. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo.Circ. Res. 2009; 104: 750-757Crossref PubMed Scopus (87) Google Scholar, 22.Witko-Sarsat V. Friedlander M. Capeillere-Blandin C. Nguyen-Khoa T. Nguyen A.T. Zingraff J. Jungers P. Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia.Kidney Int. 1996; 49: 1304-1313Abstract Full Text PDF PubMed Scopus (1633) Google Scholar), tests of antiinflammatory properties of HDL and antioxidative activity of serum may prove useful. In the present study, we investigated whether metrics of HDL composition and function predict future cardiovascular events in a cohort of nondialysis CKD patients. CARE FOR HOMe is an ongoing cohort study including patients with CKD G2–G4 according to the Modification of Diet in Renal Disease equation [estimated glomerular filtration rate (eGFR) 15–89 ml/min/1.73 m2] at baseline (23.National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am. J. Kidney Dis. 2002; 39: S1-S266PubMed Google Scholar). CARE FOR HOMe excluded transplant recipients, pregnant women, patients under the age of 18, receivers of systemic immunosuppressive medication, and patients infected with human immunodeficiency virus. Clinically apparent infections [defined as C-reactive protein (CRP) levels > 50 mg/l, and/or requiring systemic antibiotic therapy] or active malignancy at baseline were excluded. Finally, patients with acute kidney injury were excluded. All procedures involving human subjects were approved by the local Ethics Committee and carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained from all patients. At baseline, all patients provided a fasting blood and a spot urine sample. A standardized questionnaire was used to collect data, including medical history, current medication, smoking status, and prevalent diabetes mellitus. Prevalent CVD was defined as any of the following: history of myocardial infarction, coronary artery angioplasty/stenting/bypass surgery, major stroke, carotid endarterectomy/stenting, nontraumatic lower extremity amputation, or lower limb artery angioplasty/stenting/bypass surgery. All prevalent cardiovascular events were confirmed by chart review. Patients with self-reported or physician-reported diabetes mellitus, with a fasting blood glucose level of >126 mg/dl or treatment with hypoglycemic medication, were categorized as diabetic. Patients were defined as active smokers if they smoked at study start or had stopped smoking <1 month before entry into the study. Only 10 women reported estrogen treatment. Annually, we invited all patients to our study center for a follow-up examination, in which we collected information on cardiovascular events by a standardized questionnaire. Patients who became dialysis-dependent during follow-up and patients who refused to attend the regular follow-up visit were contacted by telephone, and laboratory information was provided from their treating primary care physician or their nephrologist. Two independent physicians adjudicated all events; in case of disagreement, a third physician was consulted. The primary atherosclerotic cardiovascular endpoint was defined as the first occurrence of any of the following: myocardial infarction, coronary artery angioplasty/stenting/bypass surgery, major stroke, carotid endarterectomy/stenting, nontraumatic lower extremity amputation, and/or lower limb artery angioplasty/stenting/bypass surgery, or death of any cause. As additional endpoints, we defined all-cause death as well as hospital admission for heart failure. All cardiovascular events were confirmed by chart review. A total of 544 patients were included into CARE FOR HOMe between 2008 and 2015. Serum was available from 526 patients for SAA, antioxidative activity, paraoxonase activity, Lp-PLA2 activity, HDL-C efflux capacity, and HDL-C measurements. The samples analyzed for these variables were drawn at baseline. SAA content was quantified by ELISA (human SAA, BioSource Europe S.A., Belgium) as described (24.Pertl L. Kern S. Weger M. Hausberger S. Trieb M. Gasser-Steiner V. Haas A. Scharnagl H. Heinemann A. Marsche G. High-density lipoprotein function in exudative age-related macular degeneration.PLoS One. 2016; 11: e0154397PubMed Google Scholar, 25.Trieb M. Horvath A. Birner-Gruenberger R. Spindelboeck W. Stadlbauer V. Taschler U. Curcic S. Stauber R.E. Holzer M. Pasterk L. et al.Liver disease alters high-density lipoprotein composition, metabolism and function.Biochim. Biophys. Acta. 2016; 1861: 630-638Crossref PubMed Scopus (54) Google Scholar). ApoB-depleted serum was prepared by the addition of 40 μl of polyethylene glycol (20% in 200 mmol/l glycine buffer) to 100 μl of serum. Samples were incubated for 20 min, and the supernatants were recovered after centrifugation (9,703 g, 20 min, 4°C) as described (26.Khera A.V. Cuchel M. de la Llera-Moya M. Rodrigues A. Burke M.F. Jafri K. French B.C. Phillips J.A. Mucksavage M.L. Wilensky R.L. et al.Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.N. Engl. J. Med. 2011; 364: 127-135Crossref PubMed Scopus (1533) Google Scholar, 27.Potočnjak I. Degoricija V. Trbusic M. Teresak S.D. Radulovic B. Pregartner G. Berghold A. Tiran B. Marsche G. Frank S. Metrics of high-density lipoprotein function and hospital mortality in acute heart failure patients.PLoS One. 2016; 11: e0157507Crossref PubMed Scopus (22) Google Scholar). Subsequently, the HDL-containing supernatants (apoB-depleted serum) were collected and stored at –80°C. The antioxidative activity of apoB-depleted serum was determined as previously described (24.Pertl L. Kern S. Weger M. Hausberger S. Trieb M. Gasser-Steiner V. Haas A. Scharnagl H. Heinemann A. Marsche G. High-density lipoprotein function in exudative age-related macular degeneration.PLoS One. 2016; 11: e0154397PubMed Google Scholar, 27.Potočnjak I. Degoricija V. Trbusic M. Teresak S.D. Radulovic B. Pregartner G. Berghold A. Tiran B. Marsche G. Frank S. Metrics of high-density lipoprotein function and hospital mortality in acute heart failure patients.PLoS One. 2016; 11: e0157507Crossref PubMed Scopus (22) Google Scholar). Briefly, dihydrorhodamine (DHR) was suspended in DMSO to a 50 mmol/l stock, which was diluted in HEPES (20 mmol/l HEPES, 150 mmol/l NaCl, pH 7.4) containing 1 mmol/l 2,2'-azobis-2-methyl-propanimidamide-dihydrochloride to a 50 µmol/l working reagent. One microliter of apoB-depleted serum was placed into 384-well plates, 15 µl of DHR working reagent was added, and the volume was completed to 100 µl with HEPES buffer. The increase in fluorescence due to the oxidation of DHR was measured every 2 min for 1 h at 538 nm. The increase in fluorescence per minute was determined for samples containing only DHR and for samples containing DHR and individual serum samples. Ca2+-dependent arylesterase activity of paraoxonase was determined by a photometric assay using phenylacetate as substrates as described (25.Trieb M. Horvath A. Birner-Gruenberger R. Spindelboeck W. Stadlbauer V. Taschler U. Curcic S. Stauber R.E. Holzer M. Pasterk L. et al.Liver disease alters high-density lipoprotein composition, metabolism and function.Biochim. Biophys. Acta. 2016; 1861: 630-638Crossref PubMed Scopus (54) Google Scholar, 27.Potočnjak I. Degoricija V. Trbusic M. Teresak S.D. Radulovic B. Pregartner G. Berghold A. Tiran B. Marsche G. Frank S. Metrics of high-density lipoprotein function and hospital mortality in acute heart failure patients.PLoS One. 2016; 11: e0157507Crossref PubMed Scopus (22) Google Scholar). ApoB-depleted serum was added to 200 μl of buffer containing 100 mmol/l Tris, 2 mmol/l CaCl2 (pH 8.0), and 1 mmol/l phenylacetate. The rate of hydrolysis of phenylacetate was monitored by the increase of absorbance at 270 nm, and readings were taken every 15 s at room temperature to generate a kinetic plot. The slope from the kinetic chart was used to determine ΔAb270 nm/min. Enzymatic activity was calculated with the Beer–Lambert law from the molar extinction coefficient of 1,310 l·mol−1·cm−1. HDL-associated Lp-PLA2 activity was measured in apoB-depleted serum by using a commercially available photometric assay (Cayman Europe, Talinn, Estonia) using 2-thio platelet activating factor as substrate as described previously (24.Pertl L. Kern S. Weger M. Hausberger S. Trieb M. Gasser-Steiner V. Haas A. Scharnagl H. Heinemann A. Marsche G. High-density lipoprotein function in exudative age-related macular degeneration.PLoS One. 2016; 11: e0154397PubMed Google Scholar). We quantified cholesterol efflux capacity with use of a previously published protocol (26.Khera A.V. Cuchel M. de la Llera-Moya M. Rodrigues A. Burke M.F. Jafri K. French B.C. Phillips J.A. Mucksavage M.L. Wilensky R.L. et al.Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.N. Engl. J. Med. 2011; 364: 127-135Crossref PubMed Scopus (1533) Google Scholar, 27.Potočnjak I. Degoricija V. Trbusic M. Teresak S.D. Radulovic B. Pregartner G. Berghold A. Tiran B. Marsche G. Frank S. Metrics of high-density lipoprotein function and hospital mortality in acute heart failure patients.PLoS One. 2016; 11: e0157507Crossref PubMed Scopus (22) Google Scholar, 28.Marsche G. Zelzer S. Meinitzer A. Kern S. Meissl S. Pregartner G. Weghuber D. Almer G. Mangge H. Adiponectin predicts high-density lipoprotein cholesterol efflux capacity in adults irrespective of body mass index and fat distribution.J. Clin. Endocrinol. Metab. 2017; 102: 4117-4123Crossref PubMed Scopus (29) Google Scholar). J774 cells, a mouse macrophage cell line, were plated and labeled for 24 h with 1 μCi/ml [3H]cholesterol (Perkin Elmer, Boston, MA). J774 cells express very low levels of ATP-binding cassette transporter A1 (ABCA1), an important pathway of cholesterol efflux from macrophages. To upregulate ABCA1, cells were stimulated for 6 h with serum-free DMEM containing 0.3 mmol/l 8-(4-chlorophenylthio)-cyclic AMP (Sigma, Darmstadt, Germany). After labeling, cells were washed, and [3H]cholesterol efflux was determined by incubating cells for 4 h with 2.8% apoB-depleted serum as described (26.Khera A.V. Cuchel M. de la Llera-Moya M. Rodrigues A. Burke M.F. Jafri K. French B.C. Phillips J.A. Mucksavage M.L. Wilensky R.L. et al.Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.N. Engl. J. Med. 2011; 364: 127-135Crossref PubMed Scopus (1533) Google Scholar). The quantity of [3H]cholesterol incorporated into cellular lipids was assessed by means of isopropanol extraction of [3H]cholesterol content of J774 cells not exposed to the patients' serum. All steps were performed in the presence of a concentration of 2 μg/ml of the acyl CoA cholesterol acyltransferase inhibitor Sandoz 58-035 (Sigma, Darmstadt, Germany). All assays were performed twice, and samples were assessed in duplicates. To correct for interassay variation across plates, we included a serum control on each plate, and we normalized values for serum samples from patients to this value in subsequent analyses. Across the entire cohort, duplicate measures of efflux capacity were highly correlated (r = 0.91). Categorical variables are presented as percentage of patients and compared by using the chi2 test. Continuous data are expressed as means ± SD, or median (interquartile ranges), as appropriate, and were compared by using one-way ANOVA test partitioning the between-groups sums of squares into trend components; continuous variables are presented as mean ± SD, or median (interquartile range) in case of skewed distribution. We calculated univariate correlation analyses using Spearman coefficients. For outcome analyses, we first performed Kaplan-Meier analysis with consecutive log-rank testing, after stratifying patients into tertiles by their HDL-C, SAA, antioxidative activity, paraoxonase, and Lp-PLA2 activities. Subsequently, we calculated univariate and multivariate Cox models to assess the association of a) HDL-C, b) logarithmized SAA (logSAA), c) antioxidative activity, d) paraoxonase activity, and e) Lp-PLA2 activity and cardiovascular outcome. All variables were considered both as continuous variables and as categorized variables, after stratification of patients into tertiles. We predefined multivariate Cox models with adjustment for age, gender, body mass index, mean blood pressure, smoking status, diabetes mellitus, eGFR, and log-transferred albuminuria (model 2), with additional adjustment for total cholesterol and HDL-C (for analyses with SAA, antioxidative activity, paraoxonase activity, and Lp-PLA2 activity as exposition variable) or log-transformed SAA, respectively (for analyses with HDL-C as exposition variable; model 3), and with additional adjustment for CRP (model 4). The CARE FOR HOMe consists of 526 study patients stratified by Kidney Disease: Improving Global Outcomes stages. The mean age at study entry was 65.1 ± 12.3 years with a mean eGFR of 46 ± 16 ml/min/1.73 m2 (Table 1). Of those, 39% of all patients had prevalent CVD, and about one-third had diabetes mellitus. With declining renal function, people were older and had more cardiovascular comorbidities (Table 1). Serum samples of study subjects with more advanced CKD stages showed similar HDL-C levels (Fig. 1A), increased levels of the HDL associated acute phase protein SAA (P = 0.016) (Fig. 1B), higher antioxidative activity (P < 0.001) (Fig. 1C), and lower paraoxonase activity (P = 0.011) (Fig. 1D), whereas HDL-associated Lp-PLA2 activity was not altered (Fig. 1E). In addition, we stratified the study participants by the presence of diabetes mellitus (supplemental. Fig. S1). CKD patients with diabetes mellitus showed lower HDL-C levels (P < 0.001), increased SAA (P = 0.045), lower arylesterase activity of paraoxonase (P = 0.013), and HDL associated Lp-PLA2 activity (P = 0.010) whereas antioxidative activity was not different (P = 0.935).TABLE 1Baseline characteristics, stratified by eGFR categoriesCKD G 2 (n = 112)CKD G 3a (n = 178)CKD G 3b (n = 141)CKD G 4 (n = 95)Total cohort (n = 526)p-valuesAge (years)58.8 ± 12.165.1 ± 12.568.3 ± 10.968.1 ± 11.465.1 ± 12.3≤0.001Sex (woman)38 (34%)81 (46%)61 (43%)38 (40%)218 (41%)0.252eGFR (ml/min/1.73 m2)69 ± 752 ± 438 ± 423 ± 446 ± 16≤0.001BMI (kg/m2)30.4 ± 5.430.7 ± 5.530.6 ± 6.029.5 ± 4.730.4 ± 5.50.280Diabetes mellitus (yes)40 (36%)69 (39%)54 (38%)40 (42%)203 (39%)0.827Mean BP (mmHg)108 ± 14110 ± 14105 ± 15107 ± 16108 ± 150.104Systolic BP (mmHg)149 ± 20153 ± 24150 ± 24155 ± 27152 ± 240.396Diastolic BP (mmHg)108 ± 14110 ± 14105 ± 15107 ± 16108 ± 15≤0.001Prevalent CVD (yes)18 (16%)55 (31%)61 (43%)31 (33%)165 (31%)≤0.001Current nicotine (yes)19 (17%)15 (8%)12 (9%)8 (8%)54 (10%)0.074CRP (mg/l)2.35 (1.23–4.30)2.5 (1.05–4.90)2.9 (1.2–6.4)3.3 (1.1–6-1)2.7 (1.1–5.1)0.001Triglycerides (mg/dl)157 ± 124159 ± 116165 ± 104176 ± 125163 ± 1170.210Total cholesterol (mg/dl)195 ± 39192 ± 43189 ± 44190 ± 47192 ± 430.290LDL-C (mg/dl)118 ± 35114 ± 37112 ± 36114 ± 39114 ± 360.303HDL-C (mg/dl)53 ± 1653 ± 1851 ± 1749 ± 1752 ± 170.067Lipid-lowering drugs (yes)47 (42%)100 (56%)87 (62%)52 (55%)286 (54%)0.017Statins (yes)43 (38%)94 (53%)84 (60%)50 (53%)271 (52%)0.009Lipid-lowering therapy other than statins (yes)14 (13%)16 (9%)19 (14%)7 (7%)56 (11%)0.365ApoA-I (mg/dl)166.3 ± 30.6168.1 ± 31.0164.5 ± 31.3162.1 ± 35.5165.7 ± 31.90.222ApoB (mg/dl)98.7 ± 24.6100.3 ± 26.498.0 ± 25.499.0 ± 26.499.1 ± 25.70.814Paraoxonase activity (U/ml)423.43 ± 118.45413.21 ± 104.76388.36 ± 112.51392.87 ± 122.51405.05 ± 113.690.011SAA (μg/ml)25.46 (12.61–52.68)33.13 (18.16–59.36)31.13 (14.44–58.53)30.15 (15.79–71.38)29.95 (14.96–61.75)0.016Antioxidative activity (Inhibition of oxidation in %)63.06 ± 5.2965.34 ± 5.4866.01 ± 5.9566.03 ± 5.8965.16 ± 5.74≤0.001Lp-PLA2 activity (U/ml)59.55 ± 10.3160.02 ± 11.9759.25 ± 13.0460.99 ± 9.9259.89 ± 11.580.561Values are means ± SD or interquartile ranges (in parentheses). BP, blood pressure; LDL-C, LDL cholesterol. Open table in a new tab Values are means ± SD or interquartile ranges (in parentheses). BP, blood pressure; LDL-C, LDL cholesterol. Kidney function weakly correlated with lower CRP (P = 0.031), higher HDL-C (P = 0.030), and higher paraoxonase activity (P = 0.014) (Table 2). Interestingly, kidney function was inversely associated with cholesterol efflux capacity (P = 0.006), suggesting that some metrics of HDL function are not affected and even improved in more advanced CKD stages. Moreover, kidney function was inversely associated with antioxidative activity of apoB-depleted serum (P < 0.001). The systemic inflammation marker CRP significantly correlated with lower HDL-C (P = 0.001), Lp-PLA2 activity (P = 0.001), and cholesterol efflux capacity (P < 0.001). As expected, a robust association between the systemic inflammation markers CRP and the HDL-associated SAA (P < 0.001) was observed. Further details and correlations between markers of HDL functionality are shown in Table 2.TABLE 2Univariate Spearman correlation coefficientseGFRCRPHDL-CParaoxonase activitySAAAntioxidative activityLp-PLA2 activityRhoPRhoPRhoPRhoPRhoPRhoPRhoPCRP−0.0940.031————————————HDL-C0.0950.030−0.193<0.001——————————Paraoxonase activity0.1070.014−0.0670.1230.245<0.001————————SAA−0.0730.0920.575<0.0010.0800.0650.0260.557——————Antioxidative activity−0.233<0.0010.0420.342−0.1240.0040.1280.003−0.0430.321————Lp-PLA2 activity−0.0350.428−0.1390.0010.0750.0850.1360.002−0.1110.0110.0880.045——Cholesterol efflux capacity−0.1200.006−0.1480.0010.497<0.0010.289<0.001−0.0140.7510.0700.1110.153<0.001Boldface type indicates significance (P < 0.05). Open table in a new tab Boldface type indicates significance (P < 0.05). During a mean follow-up of 5.1 ± 2.1 years, 153 patients reached the primary cardiovascular endpoint. After stratifying patients in tertiles for levels of markers of HDL-C quantity and functionality, lower levels of HDL-C (P = 0.015) and paraoxonase activity (P < 0.001) were associated with the occurrence of the primary endpoint in Kaplan-Meier analyses (Fig. 2). The primary endpoint was neither predicted by antioxidative activity (P = 0.467) nor by Lp-PLA2 (P = 0.818) nor by SAA (P = 0.054; Fig. 2). As additional endpoints, we defined all-cause death (which is majorly driven by cardiovascular death), as well as hospital admission for heart failure. We recalculated our analyses with these alternative endpoints, but did not find a substantial difference in the main results (supplemental Figs. S2 and S3). Consistently, in univariate Cox regression analyses with HDL-C quantity and function markers considered as continuous variables, lower HD" @default.
• W2804198857 created "2018-06-01" @default.
• W2804198857 creator A5011285126 @default.
• W2804198857 creator A5012419218 @default.
• W2804198857 creator A5031330531 @default.
• W2804198857 creator A5043193815 @default.
• W2804198857 creator A5045112318 @default.
• W2804198857 creator A5046342878 @default.
• W2804198857 creator A5050152515 @default.
• W2804198857 creator A5050602701 @default.
• W2804198857 creator A5065712472 @default.
• W2804198857 creator A5068160050 @default.
• W2804198857 date "2018-01-01" @default.
• W2804198857 modified "2023-10-15" @default.
• W2804198857 title "HDL functionality and cardiovascular outcome among nondialysis chronic kidney disease patients [S]" @default.
• W2804198857 cites W131901569 @default.
• W2804198857 cites W1580333051 @default.
• W2804198857 cites W1975932722 @default.
• W2804198857 cites W2018112032 @default.
• W2804198857 cites W2020779473 @default.
• W2804198857 cites W2025623225 @default.
• W2804198857 cites W2036260862 @default.
• W2804198857 cites W2042641359 @default.
• W2804198857 cites W2050185459 @default.
• W2804198857 cites W2052000579 @default.
• W2804198857 cites W2055823448 @default.
• W2804198857 cites W2067487203 @default.
• W2804198857 cites W2092952257 @default.
• W2804198857 cites W2098290541 @default.
• W2804198857 cites W2106601510 @default.
• W2804198857 cites W2109429564 @default.
• W2804198857 cites W2110318177 @default.
• W2804198857 cites W2111482014 @default.
• W2804198857 cites W2113956623 @default.
• W2804198857 cites W2116775019 @default.
• W2804198857 cites W2125326232 @default.
• W2804198857 cites W2125621282 @default.
• W2804198857 cites W2126736180 @default.
• W2804198857 cites W2136128927 @default.
• W2804198857 cites W2139976637 @default.
• W2804198857 cites W2140455131 @default.
• W2804198857 cites W2140480769 @default.
• W2804198857 cites W2144473676 @default.
• W2804198857 cites W2150691772 @default.
• W2804198857 cites W2157157967 @default.
• W2804198857 cites W2165758797 @default.
• W2804198857 cites W2167584349 @default.
• W2804198857 cites W2194982046 @default.
• W2804198857 cites W2260995852 @default.
• W2804198857 cites W2339153530 @default.
• W2804198857 cites W2385319927 @default.
• W2804198857 cites W2408344994 @default.
• W2804198857 cites W2425310808 @default.
• W2804198857 cites W2512895854 @default.
• W2804198857 cites W2518450497 @default.
• W2804198857 cites W2558875700 @default.
• W2804198857 cites W2560694811 @default.
• W2804198857 cites W2568368712 @default.
• W2804198857 cites W2679204481 @default.
• W2804198857 cites W2753582801 @default.
• W2804198857 cites W2754016730 @default.
• W2804198857 cites W2760562751 @default.
• W2804198857 cites W2786298990 @default.
• W2804198857 doi "https://doi.org/10.1194/jlr.p085076" @default.
• W2804198857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6027904" @default.
• W2804198857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29789355" @default.
• W2804198857 hasPublicationYear "2018" @default.
• W2804198857 type Work @default.
• W2804198857 sameAs 2804198857 @default.
• W2804198857 citedByCount "24" @default.
• W2804198857 countsByYear W28041988572018 @default.
• W2804198857 countsByYear W28041988572019 @default.
• W2804198857 countsByYear W28041988572020 @default.
• W2804198857 countsByYear W28041988572021 @default.
• W2804198857 countsByYear W28041988572022 @default.
• W2804198857 countsByYear W28041988572023 @default.
• W2804198857 crossrefType "journal-article" @default.
• W2804198857 hasAuthorship W2804198857A5011285126 @default.
• W2804198857 hasAuthorship W2804198857A5012419218 @default.
• W2804198857 hasAuthorship W2804198857A5031330531 @default.
• W2804198857 hasAuthorship W2804198857A5043193815 @default.
• W2804198857 hasAuthorship W2804198857A5045112318 @default.
• W2804198857 hasAuthorship W2804198857A5046342878 @default.
• W2804198857 hasAuthorship W2804198857A5050152515 @default.
• W2804198857 hasAuthorship W2804198857A5050602701 @default.
• W2804198857 hasAuthorship W2804198857A5065712472 @default.
• W2804198857 hasAuthorship W2804198857A5068160050 @default.
• W2804198857 hasBestOaLocation W28041988571 @default.
• W2804198857 hasConcept C126322002 @default.
• W2804198857 hasConcept C164705383 @default.
• W2804198857 hasConcept C177713679 @default.
• W2804198857 hasConcept C2778653478 @default.
• W2804198857 hasConcept C2779134260 @default.
• W2804198857 hasConcept C71924100 @default.
• W2804198857 hasConceptScore W2804198857C126322002 @default.
• W2804198857 hasConceptScore W2804198857C164705383 @default.
• W2804198857 hasConceptScore W2804198857C177713679 @default.
• W2804198857 hasConceptScore W2804198857C2778653478 @default.

• next